Tafinlar^® + Mekinist^® [4]

____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Tafinlar (dabrafenib) in combination with Mekinist (trametinib) is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Tafinlar (dabrafenib) in combination with Mekinist (trametinib) is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection 

Tafinlar (dabrafenib) in combination with Mekinist (trametinib) is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation

References

1. Tafinlar (dabrafenib) Summary of Product Characteristics.
2. Mekinist (trametinib) Summary of Product Characteristics.